CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Last nail in the coffin for PCI in stable angina? Comparative analysis of recurrent events after presentation with an index myocardial infarction or ischaemic stroke Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data Basic Biology of Oxidative Stress and the Cardiovascular System: Part 1 of a 3-Part Series Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial Implantable Hemodynamic Monitoring for Heart Failure Patients Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement Future of Personalized Cardiovascular Medicine

Editorial2018 Jan 6;391(10115):3-4.

JOURNAL:Lancet. Article Link

Last nail in the coffin for PCI in stable angina?

Brown DL, Redberg RF. Keywords: comment; stable angina; PCI

ABSTRACT


Interventional cardiology began in Switzerland in 1977, when Andreas Gruentzig performed the first successful percutaneous transluminal coronary angioplasty (PTCA) on a 38-year-old man with angina and a focal proximal stenosis of the left anterior descending coronary artery. Despite numerous subsequent randomised trials and meta-analyses of these trials, which have shown no reduction in death or myocardial infarction,1 the use of percutaneous coronary intervention (PCI) has grown exponentially. Some of this growth was driven by data from clinical trials suggesting that PCI was more effective in relieving angina than medical therapy alone.